Alterity Therapeutics Limited PRNAF Stock
Alterity Therapeutics Limited Price Chart
Alterity Therapeutics Limited PRNAF Financial and Trading Overview
| Alterity Therapeutics Limited stock price | 0.4 USD |
| Previous Close | 0.4 USD |
| Open | 0.4 USD |
| Bid | 0.36 USD x 250000 |
| Ask | 0.44 USD x 250000 |
| Day's Range | 0.4 - 0.4 USD |
| 52 Week Range | 0.0002 - 0.55 USD |
| Volume | 2.5K USD |
| Avg. Volume | 161 USD |
| Market Cap | 87.4M USD |
| Beta (5Y Monthly) | -0.043 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.08 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PRNAF Valuation Measures
| Enterprise Value | 50.28M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 24.210466 |
| Price/Book (mrq) | 2.835255 |
| Enterprise Value/Revenue | 13.927 |
| Enterprise Value/EBITDA | -2.004 |
Trading Information
Alterity Therapeutics Limited Stock Price History
| Beta (5Y Monthly) | -0.043 |
| 52-Week Change | 13233.33% |
| S&P500 52-Week Change | 15.74% |
| 52 Week High | 0.55 USD |
| 52 Week Low | 0.0002 USD |
| 50-Day Moving Average | 0.34 USD |
| 200-Day Moving Average | 0.09 USD |
PRNAF Share Statistics
| Avg. Volume (3 month) | 161 USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 218.5M |
| Float | 173.92M |
| Short Ratio | N/A |
| % Held by Insiders | 7.90% |
| % Held by Institutions | 17.98% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2026 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | June 30, 2027 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1816.15% |
| Gross Margin | 92.72% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -34.078% |
| Return on Equity (ttm) | -54.97% |
Income Statement
| Revenue (ttm) | 3.61M USD |
| Revenue Per Share (ttm) | 0.02 USD |
| Quarterly Revenue Growth (yoy) | -79.00000000000000000000000000000000% |
| Gross Profit (ttm) | 3.35M USD |
| EBITDA | -25090684 USD |
| Net Income Avi to Common (ttm) | -23400948 USD |
| Diluted EPS (ttm) | -0.08 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 37.32M USD |
| Total Cash Per Share (mrq) | 0.17 USD |
| Total Debt (mrq) | 193.47K USD |
| Total Debt/Equity (mrq) | 0.45 USD |
| Current Ratio (mrq) | 14.52 |
| Book Value Per Share (mrq) | 0.1410808 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -22523332 USD |
| Levered Free Cash Flow (ttm) | -14740514 USD |
Profile of Alterity Therapeutics Limited
| Country | United States |
| State | VIC |
| City | Melbourne |
| Address | 500 Collins Street |
| ZIP | 3000 |
| Phone | 61 3 9349 4906 |
| Website | https://alteritytherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 11 |
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Q&A For Alterity Therapeutics Limited Stock
What is a current PRNAF stock price?
Alterity Therapeutics Limited PRNAF stock price today per share is 0.4 USD.
How to purchase Alterity Therapeutics Limited stock?
You can buy PRNAF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Alterity Therapeutics Limited?
The stock symbol or ticker of Alterity Therapeutics Limited is PRNAF.
Which industry does the Alterity Therapeutics Limited company belong to?
The Alterity Therapeutics Limited industry is Biotechnology.
How many shares does Alterity Therapeutics Limited have in circulation?
The max supply of Alterity Therapeutics Limited shares is 218.5M.
What is Alterity Therapeutics Limited Price to Earnings Ratio (PE Ratio)?
Alterity Therapeutics Limited PE Ratio is now.
What was Alterity Therapeutics Limited earnings per share over the trailing 12 months (TTM)?
Alterity Therapeutics Limited EPS is -0.08 USD over the trailing 12 months.
Which sector does the Alterity Therapeutics Limited company belong to?
The Alterity Therapeutics Limited sector is Healthcare.
